Results 271 to 280 of about 261,254 (319)

Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg

open access: yesEuropean Journal of Rheumatology, 2020
Courtney Crayne, Randy Q. Cron
doaj  

Biomaterial design strategies for enhancing mitochondrial transplantation therapy

open access: yesBMEMat, EarlyView.
Biomaterials to facilitate mitochondrial transplantation therapy: biomaterials as barriers to protect mitochondria from pathophysiological microenvironments, like osmotic stress caused by the excessive concentration of calcium ion, reactive oxygen species, and advanced glycation end products; biomaterials integrating with biochemical cues to improve ...
Shaoyang Kang   +12 more
wiley   +1 more source

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

open access: yesBMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou   +6 more
wiley   +1 more source

Adipocytes in Aortic Stenosis: Association With Clinical and Morphological Indices

open access: yesClinical Anatomy, EarlyView.
ABSTRACT Recently, great attention has been given to understanding the new pathogenetic mechanisms underlying aortic stenosis (AS). The study aims to understand the role of mature adipocytes in AS and their association with histologic, clinical, and echocardiographic data, an area previously overlooked in AS research.
Elena Zoico   +9 more
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy